52867-93-3

Usage

Structure

A derivative of benzene with a fluorine atom at the 4th position and a 1-bromo-3-chloropropyl group at the 1st position.

Functional groups

Fluorine atom, bromine atom, chlorine atom, and a propyl chain.

Application

Used in organic synthesis and research as a building block for creating more complex chemical structures.

Intermediate

Valuable intermediate in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.

Synthesis

Can be used as a starting material for the synthesis of various fluorinated compounds due to the presence of the fluorine substituent.

Hazard

Potentially hazardous if not handled properly.

Precaution

Should be handled with care to avoid any adverse effects or accidents.

Upstream product

• 31736-75-1 3-chloro-1-(4-fluorophenyl)propan-1-ol 
• 347-93-3 3-chloro-4'-fluoropropiophenone 
• 462-06-6 fluorobenzene 

Downstream Products

• 745817-28-1 1-(4-fluorophenyl)-1-(2,4-dichlorophenoxy)-3-chloropropane 

Relevant academic research and scientific papers

Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter

Since the norepinephrine transporter (NET) is involved in a variety of diseases, the investigation of underlying dysregulation-mechanisms of the norepinephrine (NE) system is of major interest. Based on the previously described highly potent and selective NET ligand 1-(3-(methylamino)-1-phenylpropyl)-3-phenyl-1,3-dihydro-2H-benzimidaz- ol-2-one (Me@APPI), this paper aims at the development of several fluorinated methylaminebased analogs of this compound. The newly synthesized compounds were computationally evaluated for their interactions with the monoamine transporters and represent reference compounds for PET-based investigation of the NET.

1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies

New 1-[(3-aryloxy-3-aryl)propyl]-1H-imidazoles were synthesized and evaluated against Candida albicans and dermatophytes in order to develop structure-activity relationships (SARs). Against C. albicans the new imidazoles showed minimal inhibitory concentrations (MICs) comparable to those of ketoconazole, miconazole, and econazole, and were more potent than fluconazole. Several derivatives (10, 12, 14, 18-20, 24, 28, 29, 30, and 34) turned out to be potent inhibitors of C. albicans strains resistant to fluconazole, with MIC values less than 10 μg/mL. Against dermatophytes strains, compounds 20, 25, and 33 (MIC ≤ 5 μg/mL) were equipotent to ketoconazole, econazole, and miconazole. SARs of imidazoles 10-44 were rationalized with reasonable accuracy by a previously developed quantitative pharmacophore for antifungal agents.

Imidazole analogues of fluoxetine, a novel class of anti-Candida agents

Imidazole analogues of fluoxetine have been obtained by replacing the methylamino terminus of aminopropane chain with the imidazole ring. The newly designed imidazoles showed potent anti-Candida activity, superior to those of miconazole and other antifungal agents of clinical interest. 1-(4-Chlorophenyl)-l-(2,4-dichlorophenoxy)-3-(1H-imidazol-1-yl)propane (16), the most active among test imidazoles, Was about 2-fold more active and as much less cytotoxic than miconazole. High increase of activity was observed with methyl, nitro, fluorine, and chlorine (Cl > F > CH3 > NO2 > CF3).